ATRA Treatment for Hard-to-Treat Platelet Disorder
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a drug called ATRA to help people with primary ITP (a condition where the body destroys its own platelets, causing bruising and bleeding) who haven't responded well to standard treatments. The goal is to see if ATRA can safely raise platelet counts in people who need better options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with primary ITP diagnosis
- Very low platelet count (under 30 billion per liter) confirmed by two tests at least 1 day apart
- Previously tried standard ITP treatments (steroids or IV immunoglobulin) that didn't work, stopped working, or caused side effects
- No active infections, cancer, or serious heart, liver, or kidney disease
- Not pregnant, planning pregnancy, or breastfeeding
- No previous ATRA treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests a combination of two common medicines (atorvastatin and NAC) plus romiplostim to treat ITP when steroids have stopped working or stopped working. It may help raise your platelet counts.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.